Supplemental Information from Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival
Thomas A. Werfel(University of Mississippi Medical Center), Craig L. Duvall(Vanderbilt University), Taylor E. Kavanaugh(Vanderbilt University), Linus H. Lee, Somtochukwu C. Dimobi(Vanderbilt University), Violeta Sánchez(Vanderbilt University), Donna J. Hicks(Vanderbilt University), Meghan M. Joly(UL Research Institutes), Samantha M. Sarett(Vanderbilt University), Shan Wang(Shanxi Medical University), Rebecca S. Cook(Vanderbilt University), Dana M. Brantley‐Sieders(Susan G. Komen Breast Cancer Foundation), Meredith A. Jackson(Vanderbilt University), Kameron V. Kilchrist(Vanderbilt University)
Cited by 0
Related Papers
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
|Nature Communications|2016|580
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling
|Journal of Clinical Investigation|2008|276
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
|JCI Insight|2018|162
MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance
|Nature Communications|2017|159
Reactive oxygen species–degradable polythioketal urethane foam dressings to promote porcine skin wound repair
|Science Translational Medicine|2022|136